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How Much Do We Gain From Greater 
Personalisation?
Background
Stress-hyperglycaemia is a common complication in the ICU.
Glycaemic control (GC) can improve outcomes, but has been difficult
to achieve safely, increasing hypoglycaemic risk.
STAR is model-based GC with proven safety and performance. It uses
a cohort-based 2D stochastic model of patient-specific insulin
sensitivity (SI) to predict future SI distributions to dose insulin and
nutrition based on specified risk of hypoglycaemia (Figure 1).
Figure 1 – Future insulin sensitivity (SI) is forecast from current SI. The distribution of future SI is used to predict likely BG outcomes for a given 
insulin-nutrition treatment intervention.
Objectives
▪ Metabolic (SI) variability is makes GC hard to achieve safely.
→ A new 3D stochastic model is constructed to improve future SI
forecasting based on current and previous SI values.
▪ What is the impact of greater personalisation?
→ Virtual trial on validated patients assesses performance, safety
and workload.
Methods
Metabolic data from 3 clinical ICU cohorts (819 episodes and 68629
hours of treatment) are used in this study (Table 1).
Table 1 – Summary of patient demographics for three cohorts. Results are given as median [IQR] where relevant.
▪ SI is identified hourly from clinical data
▪ Bi-variate and tri-variate Gaussian kernel density methods estimate
conditional probability estimation of future SI.
▪ Cross validation is uses data from 411 (70%) episodes to build new
2D and 3D stochastic models, and tested on the other 176 (30%).
▪ Process is repeated 3 times, resulting in 528 simulated episodes.
SPRINT Christchurch STAR Christchurch STAR Gyula
# episodes 442 330 47
# hours 39838 22523 6268
% male 62.7 65.5 61.7
Age (years) 63 [48, 73] 65 [55, 72] 66 [58, 71]
APACHE II 19.0 [15.0,24.5] 21.0 [16.0,25.0] 32.0 [28.0,36.0]
LOS - ICU (days) 6.2 [2.7,13.0] 5.7 [2.5,13.4] 14.0 [8.0,20.5]
Results
Model comparison:
▪ The 2D model is over-conservative for 74% of hours mainly
where SI is within an absolute 25% change (Figure 3).
→ Indicates patients are stable more than 74% of the time.
→ Stable patients tend to remain stable.
▪ The 90% CI width in this region is reduced by 22% (Figure 2).
→ More aggressive dosing allowed for these patients.
Virtual trial simulation results: Table 2 and Figure 4
▪ Median BG is lower using the 3D model (6.0 vs. 6.3 mmol/L) for
similar high performance (90% in target band). However, tighter for
the 3D model (65% vs. 58% in 4.4-6.5 mmol/L).
▪ Slightly higher incidence of moderate hypoglycaemia for the 3D
model (3% vs. 2% < 4.4 mmol/L). No severe hypoglycaemia.
▪ Higher nutrition rates achieved with the 3D model (99 vs. 92 %GF).
Conclusions
▪ The new, more personalised 3D stochastic model provides moderately improved performance and similar safety for similar workload.
▪ The 3D model better characterises patient-specific response to insulin, allowing more optimal dosing while ensuring safety.
▪ These results justify potential clinical implementation to assess its impact on clinical outcomes.
Figure 2 – Comparison between the 3D model (colour) and the original 
2D model (green) for the 5th (a) and 95th (b) percentiles.
Figure 3 – Ratio of the 5th-95th percentile range between 3D and 2D
models. Prediction range is reduced mainly when the absolute hour-to-














































































Insulin rate CDF (whole cohort)
 
 























# patients 528 528




Median BG (mmol/L) 6.3 [5.7 6.9] 6.0 [5.5 6.7]
Insulin rate (U/h) 2.5 [1.5 4.0] 3.0 [1.5 5.0]
Nutrition (dextrose) rate 
(%GF)
92 [70 100] 99 [70 100]
%BG within 4.4-8.0 mmol/L 
(80-145 mg/dL)
90 90
%BG within 4.4-6.5 mmol/L 
(80-120 mg/dL)
58 65
%BG > 10.0 mmol/L (180 
mg/dL)
2 2
%BG <4.4 mmol/L (80 
mg/dL)
2 3
%BG <2.2 mmol/L (72 
mg/dL)
0 0
Table 2 – Simulation results of STAR using the 2D or 3D stochastic 
model. Results reported as median [IQR] where appropriate.
Figure 4 – BG level, Insulin rate , and glucose rate cdfs comparison.
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